In-vivo Imaging Market Size & Share, by End user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations [CROs]); Application; Technology; Modality; Reagents; Business Mode - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

In-Vivo Imaging Market - Regional Analysis

North America Market Insights

North America in the in-vivo imaging market is projected to emerge as the dominating region by garnering the largest share of 40.5% by the end of 2035. The market’s growth in the region is propelled by early adoption, technological leadership, suitable research and development (R&D), an increase in health spending, microscope sourcing, and a supportive administrative framework. According to an article published by PSNET in March 2023, alerts and alarms are essential while utilizing clinical decision support (CDC) tools, thereby denoting 44.8% overridden alerts and 9.3% inappropriate alerts. Besides, with this installation for technological integration, a 90% accuracy rate was recorded across two facilities, thus suitable for the market’s upliftment.

The in-vivo imaging market in the U.S. is growing significantly, owing to the presence of biotech and pharma organizations, federal research funding, private investments, clinical demands, and a strong supply chain administration. As stated in the January 2024 ITA report, medical devices in the healthcare sector, which is estimated at a valuation of USD 128.1 million, continue to ensure suitable prospects for the country’s exporters. As one of the topmost suppliers, the country readily exports medical devices and has witnessed a 25% growth over the past 3 years, thus denoting a huge opportunity for the market to flourish.

The in-vivo imaging market in Canada is also growing due to health care modernization by the government, publicly funded research activities, focus on affordable and equitable accessibility, the presence of robust research clusters, and aging demographic pressure. As per the December 2024 Government of Canada report, the National Strategy for Drugs for Rare Diseases has been formed and allocated an ongoing funding of USD 500 million each year. The purpose of this fund is to focus on future phases and assist individuals with rare disorder drugs accessibility as per their demand, which creates an optimistic outlook for the market in the country.

Microscopes 2023 Export and Import in North America

Source: OEC, July 2025

APAC Market Insights

Asia Pacific in the in-vivo imaging market is considered to emerge as the fastest-growing region by the end of the projected timeline. The market’s development in the region is highly driven by modernization in healthcare infrastructures, a surge in health spending and insurance coverage, R&D migration in pharmaceutical manufacturing, and the growing medical tourism sector. According to an article published by NLM in February 2023, an estimated 4% to 7% of total gross domestic product (GDP) has been readily invested in the health industry in the majority of the region. Besides, the Open Access Government Organization data report published in July 2025 noted that there will be an increase in the elderly population from 77.4 million over the past 5 years to 173.3 million by the end of 2050.

The in-vivo imaging market in China is gaining increased traction, owing to the existence of the domestic innovation policy, centralized procurement facilities, volume-based purchase activities, rapid expansion in private health industries, and AI implementation as a national priority. As stated in the May 2023 NLM article, with assistance from the government, there has been the establishment of an overall 1,030,935 health and medical institutions in the country, along with the presence of 36,570 hospitals, as well as 977,790 primary-based clinics, thereby suitable for boosting the market’s exposure.

The in-vivo imaging market in India is also growing due to medical advancements, suitable centers for clinical trials and generic drugs, the demand for public health schemes, and tiered healthcare system, and regional manufacturing processes. In this regard, the January 2025 PIB report denoted that over 73 crore (730 million) Ayushman Bharat Health Accounts (ABHA) have been created, along with recording over 5 lakh registered health professionals. In addition, Gujarat, Madhya Pradesh, Maharashtra, Uttar Pradesh, and Rajasthan accounted for 49.1% of total women beneficiaries.

Europe Market Insights

Europe in the in-vivo imaging market is expected to account for a considerable share during the projected timeline. The market’s upliftment in the region is effectively fueled by domestic regulatory funding frameworks, focus on cross-border standardization in healthcare, the existence of public and academic industrial consortia, and quality-based systems. As stated in the May 2025 European Commission report, the World Health Organization (WHO) noted that 12.6 million deaths take place, owing to environmental risk factors, which further account for 20% of deaths in the region. Besides, according to the 2024 OECD report, more than 40% of doctors from Switzerland, Ireland, and Norway, along with over 50% of Irish nurses, were foreign-trained, capable enough to administer and manage health imaging in the region.

The in-vivo imaging market in Germany is steadily growing, owing to regional manufacturing and engineering leadership, hospital investment incentives, an increase in the density of maximal care hospitals, and standard reimbursement procedures. As per the December 2024 NLM article, it is mandatory for any patient over 18 years of age comprising health insurance to pay 10 euros per day to hospitals for meals and accommodation. Besides, as per the 2023 OECD data report, there has been a surge in the country’s health expenditure, amounting to EUR 5,159 per capita. In addition, the public funding share for healthcare over the past 4 years was 85.5%, denoting a rise from 81.1%.

The in-vivo imaging market in France is also growing due to the provision of strategic plans by the National Cancer Institute (INCa), the presence of centralized procurement and planning, focus on healthcare equality, and government-based innovative developments. For instance, as per the 2025 UICC report, 20 million cancer cases have been estimated to take place as of 2022, which is anticipated to increase to 35 million, denoting a 77% increase by the end of 2050. However, to overcome this, the UICC in the country, comprising more than 1,150 members, has focused on partnerships to develop networks, which in turn, is suitable for the overall market.

Medical Instruments 2023 Export and Import in Europe

Source: OEC, August 2025